ES2157250T3 - Composicion para el tratamiento de tumores y la inmunizacion de organismos contra tumores. - Google Patents

Composicion para el tratamiento de tumores y la inmunizacion de organismos contra tumores.

Info

Publication number
ES2157250T3
ES2157250T3 ES94907603T ES94907603T ES2157250T3 ES 2157250 T3 ES2157250 T3 ES 2157250T3 ES 94907603 T ES94907603 T ES 94907603T ES 94907603 T ES94907603 T ES 94907603T ES 2157250 T3 ES2157250 T3 ES 2157250T3
Authority
ES
Spain
Prior art keywords
tumors
cells
composition
viruses
immunization
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94907603T
Other languages
English (en)
Inventor
Claude Roth
Philippe Kourilsky
Lluis Mir
David Klatzmann
Jean-Loup Salzmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universite Pierre et Marie Curie Paris 6
Assistance Publique Hopitaux de Paris APHP
Institut Pasteur de Lille
Institut National de la Sante et de la Recherche Medicale INSERM
Original Assignee
Universite Pierre et Marie Curie Paris 6
Assistance Publique Hopitaux de Paris APHP
Institut Pasteur de Lille
Institut National de la Sante et de la Recherche Medicale INSERM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9444308&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2157250(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Universite Pierre et Marie Curie Paris 6, Assistance Publique Hopitaux de Paris APHP, Institut Pasteur de Lille, Institut National de la Sante et de la Recherche Medicale INSERM filed Critical Universite Pierre et Marie Curie Paris 6
Application granted granted Critical
Publication of ES2157250T3 publication Critical patent/ES2157250T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2026—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2046—IL-7
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/13—Tumour cells, irrespective of tissue of origin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

COMPOSICION DESTINADA A TRATAR LOS TUMORES DE ORGANISMOS HUMANOS O ANIMALES Y EN INMUNIZAR ESTOS ORGANISMOS CONTRA TUMORES, COMPRENDIENDO DICHA COMPOSICION EN ASOCIACION SINERGICA: CELULAS, VIRUSES, O BACTERIAS QUE EXPRESAN DE MANERA TRANSITORIA EN EL ORGANISMO AL MENOS UN GEN QUE LES PERMITE PRODUCIR IN VIVO UNO O VARIOS INMUNOMODULADORES, Y VIRUSES O CELULAS QUE PRODUCEN VIRUSES, INFECTANDO PREFERENTEMENTE DICHOS VIRUSES A LAS CELULAS EN DIVISION DEL ORGANISMO TRATADO Y QUE LLEVA EN SU GENOMA AL MENOS UN GEN CUYA EXPRESION EN LAS CELULAS EN DIVISION VA A CONLLEVAR SU MUERTE.
ES94907603T 1993-02-22 1994-02-21 Composicion para el tratamiento de tumores y la inmunizacion de organismos contra tumores. Expired - Lifetime ES2157250T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9302012A FR2699082B1 (fr) 1993-02-22 1993-02-22 Composition pour le traitement de tumeurs et l'immunisation d'organismes à l'encontre de tumeurs.

Publications (1)

Publication Number Publication Date
ES2157250T3 true ES2157250T3 (es) 2001-08-16

Family

ID=9444308

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94907603T Expired - Lifetime ES2157250T3 (es) 1993-02-22 1994-02-21 Composicion para el tratamiento de tumores y la inmunizacion de organismos contra tumores.

Country Status (14)

Country Link
US (1) US6090378A (es)
EP (2) EP1097714A1 (es)
JP (1) JPH08507757A (es)
AT (1) ATE200984T1 (es)
AU (1) AU6111294A (es)
CA (1) CA2156635A1 (es)
DE (1) DE69427188T2 (es)
DK (1) DK0684842T3 (es)
ES (1) ES2157250T3 (es)
FR (1) FR2699082B1 (es)
GR (1) GR3036049T3 (es)
PT (1) PT684842E (es)
SG (1) SG49210A1 (es)
WO (1) WO1994019022A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5795929A (en) * 1997-04-22 1998-08-18 Koch Enterprises, Inc. Polymer enhanced asphalt emulsion
AU9603898A (en) * 1997-10-09 1999-05-03 Pro-Virus, Inc. Treatment of neoplasms with viruses
US7470426B1 (en) 1997-10-09 2008-12-30 Wellstat Biologics Corporation Treatment of neoplasms with viruses
US7780962B2 (en) 1997-10-09 2010-08-24 Wellstat Biologics Corporation Treatment of neoplasms with RNA viruses
US20030044384A1 (en) 1997-10-09 2003-03-06 Pro-Virus, Inc. Treatment of neoplasms with viruses
CN1477964A (zh) 1999-04-15 2004-02-25 应用病毒治疗肿瘤
US8147822B1 (en) 1999-09-17 2012-04-03 Wellstat Biologics Corporation Oncolytic virus

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5061488A (en) * 1988-04-15 1991-10-29 The United States Of America As Represented Department Of Health & Human Services Flavone-8-acetic acid and interleukin-2 for cancer therapy
DK0551401T3 (da) * 1990-09-14 1996-01-22 Univ Texas Fremgangsmåde og præparater til genterapi og potensering af antitumor-immunitet
JPH06509578A (ja) * 1991-07-26 1994-10-27 ユニバーシティ・オブ・ロチェスター 悪性細胞利用による癌治療法
US5529774A (en) * 1991-08-13 1996-06-25 The Regents Of The University Of California In vivo transfer of the HSV-TK gene implanted retroviral producer cells
AU675948B2 (en) * 1992-05-01 1997-02-27 United States Of America, As Represented By The Secretary, Department Of Health And Human Services, The Bystander effect tumoricidal therapy

Also Published As

Publication number Publication date
PT684842E (pt) 2001-08-30
GR3036049T3 (en) 2001-09-28
JPH08507757A (ja) 1996-08-20
US6090378A (en) 2000-07-18
AU6111294A (en) 1994-09-14
FR2699082B1 (fr) 1995-05-05
FR2699082A1 (fr) 1994-06-17
EP1097714A1 (fr) 2001-05-09
ATE200984T1 (de) 2001-05-15
DE69427188T2 (de) 2001-09-20
CA2156635A1 (fr) 1994-09-01
DE69427188D1 (de) 2001-06-13
EP0684842A1 (fr) 1995-12-06
SG49210A1 (en) 1998-05-18
WO1994019022A1 (fr) 1994-09-01
EP0684842B1 (fr) 2001-05-09
DK0684842T3 (da) 2001-06-18

Similar Documents

Publication Publication Date Title
MX2021012285A (es) Compuestos de piperidina 3-sustituidos para inhibicion del protooncogen-b de linfoma de linea b de casitas (cbl-b) y uso de un inhibidor de cbl-b en combinacion con una vacuna contra el cancer y/o con un virus oncolitico.
HUP0203523A2 (hu) Bakteriofágokkal társuló lizáló enzimek használata különböző betegségek megelőzésére és kezelésére
Weichman et al. Laser use in endodontics: Part II
UY25869A1 (es) Moduladores de ccr5, formulaciones farmacéuticas, procedimientos y sus usos.
DK0653911T3 (da) Fremgangsmåder til inaktivering af bakterier i blodpræparater med 8-methoxypsoralen
ES2032316T3 (es) Procedimiento para la esterilizacion de plasma o fracciones de plasma.
BRPI0414331A (pt) método de destruição de bactéria numa área de tratamento do paciente e composição antimicrobiana de terapia fotodinámica
ES2120274T3 (es) Utilizacion de un extracto de una bacteria filamentosa no fotosintetica y composicion.
PA8547601A1 (es) Inhibidores de la proteasa del vih, composiciones que los contienen, sus usos farmaceuticos y materiales para su sintesis
ES2181725T3 (es) Inhibidores de hiv proteasa.
BR0315088A (pt) Métodos para produção de um efeito antiangiogênico e/ou redutor de permeabilidade vascular em um animal de sangue quente e para tratamento de câncer em um animal de sangue quente, composição farmacêutica, kit, e, uso de zd6474 ou de um sal fermaceuticamento aceitável do mesmo e gencitabina
ES2061673T3 (es) Inactivacion de virus y bacterias.
BR0007692A (pt) Processo para tratar um volume selecionado de tecido, e, agente para tratamento de tecido
ATE311853T1 (de) Verwendung von krillenzymen zur behandlung von zahnbelag
ATE415962T1 (de) Verwendung von asiatsäure oder asiaticosid zur behandlung von krebs
ATE238792T1 (de) Verwendung von makroliden zur behandlung von glaukom
ES2157250T3 (es) Composicion para el tratamiento de tumores y la inmunizacion de organismos contra tumores.
SE9701161D0 (sv) New use I
AR030540A1 (es) Compuestos antipicornavirales y composiciones, su uso farmaceutico, y materiales para su sintesis
DE19580890D2 (de) Lebendvakzine zur Behandlung von Tumorerkrankungen
MX2022004055A (es) Composicion novedosa para el cuidado de la piel.
EA199700241A1 (ru) Новые, определенные по составу смеси ферментов для выделения клеток и лечения ран
BR112022007844A2 (pt) Composição antimicrobiana, método não terapêutico de tratamento da pele e/ou cavidade oral de mamíferos e uso não terapêutico de composição
ES2110057T3 (es) Composicion medicinal que contiene tcf-ii.
MX9300203A (es) Compuestos policiclicos disubstituidos y composicion farmaceutica que los contiene.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 684842

Country of ref document: ES